Technology ID
TAB-4916
Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design
E-Numbers
E-102-2014-0
Lead Inventor
Kepler, Thomas
Lead IC
NIAID
Co-Inventors
Mascola, John
Haynes, Barton
Boyd, Scott
Fire, Andrew
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Antibodies
The technology focuses on developing clonal lineage antibodies targeting the CD4 binding site of HIV-1, serving as templates for an effective HIV-1 vaccine. Developed through collaboration with Duke, Boston, and Stanford Universities, the patent filed by Duke University in 2012. These antibodies exhibit neutralizing activity against HIV-1, designed for therapeutic and prophylactic benefits, targeting a critical site of vulnerability on the virus to stimulate the immune system. Currently in the discovery stage, ongoing research focuses on characterizing antibodies and optimizing their efficacy as vaccine candidates, potentially revolutionizing HIV-1 vaccine development with a novel and targeted approach.
Commercial Applications
The technology holds promise for diverse applications, particularly in vaccine development and therapeutic antibody production. By targeting the CD4 binding site of HIV-1, these clonal lineage antibodies could serve as potent templates for an effective HIV-1 vaccine, addressing a critical need in global health. Additionally, the antibodies may be utilized as therapeutic agents for treating HIV-1 infection, offering a novel approach to managing the disease. Beyond HIV-1, the technology's innovative targeting strategy could be adapted for other infectious diseases or cancer, where similar molecular targets are present, potentially revolutionizing treatment approaches in these areas as well.
Competitive Advantages
The technology offers several competitive advantages in the field of HIV-1 vaccine design. Firstly, the approach targets the CD4 binding site, a critical and conserved region of the virus, which allows for the development of broadly neutralizing antibodies effective against a wide range of HIV-1 strains. This specificity enhances the potential efficacy of the vaccine compared to traditional approaches. Additionally, the collaboration with leading universities has enabled access to cutting-edge research and expertise, ensuring that the technology remains at the forefront of innovation in the field. Furthermore, the patent protection provides a strong foundation for commercialization, offering a unique and valuable asset in the competitive landscape of HIV-1 vaccine development.
Licensing Contact: